15 Microcap Ideas on My Watchlist
Monopolies, turnarounds, and regulatory tailwinds the market hasn't priced in yet.
To read our full disclaimer, click here.
Every so often I like to step back from the deep dives and share a broader sweep of what I’m watching.
These are 15 microcap (and near-microcap) names that have caught my attention.
None of these are full positions -they’re watchlist names at various stages of diligence.
The common thread: real businesses, identifiable catalysts, and some reason the market isn’t paying attention yet.
Cybeats Technology (CYBT.CN)
Cybeats is a pure-play on Software Bill of Materials (SBOM) regulations, which are rapidly becoming mandatory for any company selling software to the U.S. government or defense sector. Their SBOM Studio platform lets enterprises produce, manage, and act on SBOMs -and they’re the sole provider of an enterprise-grade platform in this niche. Revenue is growing 50%+ YoY with contracts from names like Schneider Electric and U.S. government agencies. As compliance requirements spread from defense into broader enterprise, Cybeats sits at the chokepoint. This is a regulatory-driven TAM expansion story with high operating leverage as renewals compound. Still tiny, still early, and still largely unknown.
Cloudastructure (CSAI)
Cloudastructure has built an AI platform that monitors live video surveillance cameras and sends real-time alerts to operations teams. They serve the multi-family sector and are growing fast. There’s some historical baggage here -the founder was convicted in a stock promotion scheme, was fired, and has been dumping shares since, which keeps the price depressed. But the underlying business is real and scaling. At a ~$43m fully diluted market cap, it’s worth noting that a private competitor, Spot AI, recently raised at a $100m valuation. If the overhang from the founder’s selling eventually clears, the gap between private and public market valuations could close quickly.
TAT Technologies (TATT)
Commercial aviation is entering a prolonged MRO supercycle. Fleets are aging globally, new aircraft deliveries are delayed, and airlines have no choice but to maintain what they’ve got. TAT provides heat exchangers, APUs, and landing gear MRO - the unsexy but essential plumbing of aircraft maintenance. Q3 2025 revenue grew 14% YoY to $46m, with gross margins at 25% and expanding. They’ve now delivered nine consecutive quarters of revenue growth and sit on a $524m backlog. Multiple analysts have raised targets north of $55. With Q4 results expected in late March and management explicitly exploring accretive acquisitions, this looks like a compounder hiding in plain sight.
Ascent Industries (ACNT)
This is a textbook turnaround. Ascent sold off its legacy tubular divisions for ~$61m, emerged debt-free with $58m in cash, and is now executing as a pure-play specialty chemicals platform. Q3 2025 was the proof point: gross profit nearly doubled, gross margin expanded over 1,500 basis points to ~30%, and adjusted EBITDA turned positive. They’ve repurchased 7.2% of shares outstanding and authorized a new buyback through 2027. A new contract is expected to generate over $10m in incremental annualized revenue. When a company goes from messy conglomerate to focused, debt-free, and buying back stock -that’s the kind of inflection that gets re-rated.
WidePoint (WYY)
The numbers here are almost comically asymmetric. WidePoint has 10 million shares outstanding, no bank debt, $12m in cash, and a $269m contract backlog. They are awaiting award of the DGS CWMS 3.0 - a $3 billion, 10-year government contract vehicle - against a $51m market cap. The award is expected by end of Q1 or early Q2 2026. If it comes through, the stock is wildly mispriced. If it doesn’t, the existing backlog still underpins significant value. This is an event-driven setup where the market seems to be assigning near-zero probability to a transformative outcome.
SANUWAVE Health (SNWV)
SANUWAVE dominates a niche in wound care with its UltraMIST Therapy System - a painless, non-contact ultrasound device. The model is high-margin razor/razor-blade: 60% of revenue is recurring. Under CEO Morgan Frank, the company executed a major turnaround, recruiting elite sales leadership from Abiomed. 2025 saw some industry headwinds around skin-substitute reimbursements, but SANUWAVE is positioned for a 2026 tailwind as wound -care distributors seek alternative revenue streams. Projected 30% growth with improving EBITDA and significant operating leverage as the commercial team scales. A real business with real recurring revenue at a microcap price.
Cematrix (CEMX)
Cematrix has been around for years and still trades under $1, but it’s profitable, about to report a record year for 2025, and its backlog keeps growing even as revenues rise - pointing to another record year in 2026. The company is essentially a monopoly in its niche of cellular concrete solutions. Beyond organic growth, it’s now in a position to be an acquirer. The main risk is cyclicality in the construction industry, but the competitive moat here is unusually wide for a sub-$1 stock. Scaling itself out of the bargain basement.
BeWhere Holdings (BEW.V)
BeWhere is a consistently profitable mobile IoT asset-tracking business that’s now pivoting from hardware-focused sales to subscription-based recurring revenue. That transition - from lumpy product sales to predictable SaaS-like streams - is exactly the kind of shift that drives re-ratings in small companies. The company just announced a C$4m brokered LIFE offering, signaling the pivot to wider institutional ownership is underway. At the cusp of going from “unknown microcap” to “institutionally owned compounder.”
Atlas Engineered Products (AEP.V)
AEP is rolling up and automating the manufacturing of wood roof trusses, floor trusses, and wall panels for Canadian residential construction. They’ve been prudent through the housing downturn and are positioned to take market share as building activity recovers. At the current depressed price, even modest signs of a homebuilding recovery could lead to significant appreciation. This is a picks -and-shovels play on Canadian housing with consolidation economics - buy fragmented local manufacturers cheaply, centralize operations, and ride the cycle back up.
NeurAxis (NRXS)
NeurAxis has arguably cleared the hardest part of its journey. The company’s IB-Stim device for pediatric functional abdominal pain has achieved inclusion in the pediatric guidelines, secured a Category 1 CPT reimbursement code, and obtained major insurance coverage. The only real question now is speed of scaling. Notably, the one analyst covering the stock has not included VA revenue in their model -and the VA market opportunity is in the double-digit billions, roughly the same size as the pediatric opportunity. If execution continues, NRXS could be dramatically underestimated by the market simply because no one’s modeling the full TAM.
Garrett Motion (GTX)
Garrett makes turbochargers and has successfully bridged into higher-tech electric and hybrid products. The company emerged from bankruptcy in 2021 and has been well-run since, consistently producing cash and paying down debt. Low valuation multiples are expanding as the balance sheet de-risks. This isn’t a moonshot -it’s a boring, steady compounder that the market still treats with post-bankruptcy skepticism. As that stigma fades and cash generation continues, the re-rating should follow.
High Tide (HITI)
High Tide is the dominant cannabis retailer in Canada with a 12% national market share and a 2.5-million-member loyalty program called Cabana Club. CEO Raj Grover has built the moat using a “Discount Club Model” that prioritizes volume and customer loyalty over high margins. The company is now expanding internationally - acquiring a majority stake in Germany’s Remexian Pharma to enter the European medical market. Cash-flow positive, scaling, and waiting for U.S. federal rescheduling to unlock the next leg of growth. Trading at a modest EV/EBITDA multiple relative to its projected $700m 2026 revenue, this is a rare cannabis name that actually generates cash.
Koil Energy (KLNG)
Koil provides critical “plumbing” and engineering services for subsea offshore energy infrastructure. Since 2024, CEO Erik Wiik has led a rapid turnaround, converting losses into profits and growing revenue by 40% while competitors contracted. The three-year strategic plan focuses on capturing share in new basins - Brazil, North Sea -without needing oil prices to rise. This is a lean, high-growth play on offshore energy services with geographic expansion as the primary driver. The market hasn’t caught on yet.
NameSilo Technologies (URL.CN)
NameSilo is a domain registrar business that generates recurring cash flow from millions of domain renewals. Think of it as a boring utility for the internet economy. The interesting part is capital allocation: under Paul Andreola - a well-known microcap stock picker - the company is using that cash flow to acquire businesses and build out a mini-platform. Recent acquisitions include SewerVUE (sewer inspection robots) and Reach Systems (vertically integrating engineering and manufacturing). The domain business provides the steady base; acquisitions provide the upside optionality. If management continues to allocate capital intelligently, this is the kind of quiet compounder that looks obvious in hindsight.
Paragon Advanced Labs (PALS.V)
Paragon is a high-growth mining services company specializing in high-speed mineral testing via PhotonAssay technology. This is meaningfully faster and more accurate than traditional fire assay methods, which gives them a real competitive edge as mining activity ramps. Management projects rapid scaling, with 2027 EBITDA expected to hit $19m -a ~110% increase over 2026 estimates. Currently trading at just 6x 2027 EV/EBITDA, compared to slower-growing industry peers at 10-12x. A picks-and-shovels play on the commodities cycle with a disruptive technology edge.
As always, these are watchlist names.
Several could end up as full write-ups if diligence deepens the thesis. The common denominator is that each has a real business, identifiable catalysts, and a reason the market isn’t fully pricing in the opportunity.
Dom
Schwar Capital
Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Schwar Capital. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. You can see our full disclaimer here.